Celcuity Shares Climb Nearly 8% as Cantor Fitzgerald Backs Breast Cancer Drug Maker Ahead of Key ESMO Data
Celcuity Inc. shares rose 7.78% after Cantor Fitzgerald initiated coverage with an overweight rating and a $140 price target, citing growth potential of its breast cancer drug, Revtorpyk. The company will present key clinical data at the ESMO Congress this weekend. Analysts are bullish, with price targets ranging from $130 to $177, despite a 50% stock decline over six months.
How this was made
The 30-second read
Why it matters
Analyst upgrades and a strong price target suggest a short‑term rally, but long‑term performance hinges on trial outcomes and sales uptake.
Market read
The coverage upgrade sparked an 8% intraday rise, indicating immediate trading relevance.
What to watch
Potential reimbursement challenges and competition from other PI3K/mTOR inhibitors.
Background
Celcuity recently launched Revtorpyk for HR‑positive, HER2‑negative breast cancer and is awaiting Phase 3 data at ESMO.
Market effects
Positive sentiment may lift other early‑stage oncology biotech stocks.
U.S. biotech sector could see modest gains in early trading.
Limited to U.S. and international investors tracking biotech pipelines.
Counterpoint
The stock remains volatile after a 50% decline; the new data risk remains high.
Key entities
- companyCelcuity Inc.
U.S. biotech developing gedatolisib (Revtorpyk).
- analystCantor Fitzgerald
Initiated coverage with an overweight rating and $140 target.
